Jacob Leach compensation by year
DEXCOM Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $409,406 | $450,000 | $534,743 | $625,053 | $682,498 | $768,962 |
| Bonus | $0 | $0 | $0 | $0 | — | $0 |
| Stock awards | $3,366,495 | $4,792,343 | $3,433,079 | $3,648,340 | $5,229,163 | $5,936,062 |
| Option awards | $0 | $0 | $0 | $0 | — | $0 |
| Non-equity incentive | $525,063 | $442,125 | $437,153 | $656,305 | — | $1,164,780 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | — | $0 |
| All other | $69,618 | $23,805 | $22,233 | $8,325 | $10,610 | $116,156 |
| Total | $4,370,582 | $5,708,273 | $4,427,208 | $4,938,023 | $5,922,271 | $7,985,960 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: DEXCOM INC DEF 14A filed April 15, 2026, accession 0001093557-26-000061, and prior-year filings. Open the filing on EDGAR.
How this page was built: the DEXCOM INC filed document, accession 0001093557-26-000061. Every figure is read from that document and cited to the page and table it appears in. Filed April 15, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 92,847 | $6,162,255 | — |
| RSU | 35,906 | $2,383,081 | — |
| RSU | 22,798 | $1,513,103 | — |
| RSU | 17,368 | $1,152,714 | — |
| PSU | 15,389 | $1,021,368 | — |
| RSU | 15,389 | $1,021,368 | — |
| RSU | 8,465 | $561,822 | — |
| RSU | 8,310 | $551,535 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in DEXCOM INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2025 proxy (filed April 15, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-22 | Tax withholding | — | 1,451 | $92.34 | 418,908 |
| 2026-05-22 | Tax withholding | — | 1,451 | $71.90 | 420,359 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments DEXCOM discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $800,000 | $0 | $27,024 | $1,533,609 |
| Change in control and involuntary termination | $1,600,000 | $7,113,736 | $54,048 | $10,180,954 |
Per the Potential Payments Upon Termination or Change in Control table in DEXCOM INC's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
DEXCOM’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Kevin Sayer | Executive Chairman | $16,282,598 |
| Jacob Leach · this page | President & Chief Executive Officer | $7,985,960 |
| Jereme Sylvain | EVP, Chief Financial Officer | $7,077,902 |
| Jon Coleman | EVP, Chief Commercial Officer | $6,745,295 |
| Michael Brown | EVP, Chief Legal Officer | $6,343,856 |
| Sadie Stern | EVP, Chief Human Resources Officer | $6,253,131 |
Board service
DEXCOM board · FY2022–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $0 | $0 | $0 | $0 | — |
| FY2023 | $0 | — | — | $8,325 | $8,325 |
| FY2022 | $0 | — | — | $22,233 | $22,233 |
Each year as the company reported it in DEXCOM's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: DEXCOM pays directors a $0 cash retainer and $325,000 in RSUs. As stated in DEXCOM's FY2025 proxy.
The full DEXCOM compensation record
free company briefThis page is one person within DEXCOM's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the DEXCOM proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order DEXCOM's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are DEXCOM's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order DXCM
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.